Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
treatment-resistant depression
Biotech
Supernus depression drug candidate fails midstage trial
Patients given SPN-820 showed no improvement in their Montgomery-Åsberg Depression Rating Scale scores, a measure of symptom severity.
Darren Incorvaia
Feb 19, 2025 6:40am
Compass delays phase 3 psychedelic data, lays off 30% of staff
Oct 31, 2024 9:00am
Abbott begins neuromodulation trial in drug-resistant depression
Sep 4, 2024 11:02am
Motif Neuro raises $19M for brain pacemaker depression treatment
Jan 24, 2024 10:17am
Motif implants pea-sized 'brain pacemaker' for depression
Sep 18, 2023 10:34am
Alvogen snags NRx's bipolar depression drug in $330M deal
Jun 7, 2023 6:30am
